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Emery-Dreifuss muscular dystrophy (EDMD) is a hereditary neuromuscular disorder characterized by slowly progressive muscle
weakness, early contractures, and dilated cardiomyopathy. We reported an uneventful general anaesthesia using total intravenous
anaesthesia (TIVA) for cardiac transplantation in a 19-year-old woman suffering from EDMD. In vitro contracture test results of
two pectoralis major muscle bundles of the patient suggest that exposition to triggering agents does not induce a pathological
sarcoplasmic calcium release in the lamin A/C phenotype. However, due to the lack of evidence in the literature, we would
recommend TIVA for patients with EDMD if general anaesthesia is required.
1. Introduction
Emery-Dreifuss muscular dystrophy (EDMD), initially con-
sidered a benign form of Duchenne or Becker muscular
dystrophy, is a hereditary neuromuscular disorder charac-
terized by slowly progressive muscle weakness at the outset
with humeroperoneal distribution and early contractures
of elbow joints, Achilles tendons, and posterior-cervical
muscles. EDMD either presents as an X-linked disorder due
to a mutation in the emerin gene on chromosome Xq28
or as an autosomal dominant form, associated with an
aberration of lamin A/C proteins on chromosome 1q11-
23 [1]. Emerin and lamin A/C are located in the inner
nuclear membrane of different cell types, including skeletal
und cardiac muscle fibers. The incidence of autosomal
dominant EDMD varies from 1 to 3 : 100.000, while the
prevalence of the X-linked recessive form is assumed with 1
in 100.000males [2]. Cardiac disease occurring by adulthood
is a predominant feature of EDMD comprising conduction
defects and arrhythmias. Implantation of a pacemaker is
recommended if sinus or AV node disease develops [3, 4].
Heart transplantations due to dilated cardiomyopathy and
heart failure are rare, but may increase as patients with
a pacemaker or cardioverter/defibrillator may have longer
survival [5].
2. Case Report
After obtaining written informed consent of a 19-year-
old woman with a lamin A/C associated EDMD scheduled
for high urgent cardiac transplantation we reviewed the
specific anaesthetic management of this case and presented
histological findings of skeletal and heart muscle and results
of in vitro contracture-testing.
Beside minor weakness of anterior cervical muscles and
proximal upper limbs preoperative neurologic examination
was unremarkable. After surviving a sudden cardiac arrest
in 2005 an implantable cardioverter defibrillator (ICD) had
been inserted. During the last 3 years, she had frequently
been hospitalized because of congestive heart failure. Cardiac
evaluation revealed an ongoing progression towards dilated
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Table 1: Metabolic parameters at different points of time during cardiac transplantation.
FiO2 pH
PCO2
[mmHg]
PO2
[mmHg]
Base excess
Laktate
[mmol/L]
Creatinkinase [U/L]
reference value:
<170U/L
Myoglobin [µg/L]
reference value:
25–58 µg/L
Temp. ◦C
Initial 0.21 7.5 34 62 3.4 0.8 53 30 37.2
Reperfusion 1.0 7.25 44 235 −7.7 8.4 53 56 36.3
After weaning from CPB
(central venous)
1.0 7.29 47 59 −7.6 9.5 729 830 36.9
Admission on ICU 0.4 7.32 46 156 −1.9 — 1357 1283 36.3
1 postoperative day 0.35 7.41 48 122 5.8 — 1292 1005 —
cardiomyopathy despite maximum medical therapy. Periop-
erative echocardiography showed left ventricular and atrial
dilatation, an ejection fraction of 22%, moderate tricuspid
regurgitation, and an increased systolic pulmonary arterial
pressure of 71mmHg. ECG showed a regular sinus rhythm
with incomplete right bundle branch block. After a 3-month
waiting period, orthotopic bicaval cardiac transplantation
was carried out. Prior to arrival at the operating room,
the anaesthetic workstation (Dra¨ger Primus, Germany)
was prepared according to our standardized procedure for
patients with known malignant hyperthermia susceptibility
or muscular disorders: Vapors were removed, carbon diox-
ide absorbent, fresh gas hose, and breathing circuit were
exchanged and the system was flushed with a fresh gas flow
of 18 L/min for at least 25min. Prior to surgery, arterial,
central venous, and pulmonary artery catheters for hemo-
dynamic monitoring were inserted under local anaesthesia.
Preoperative arterial blood gases (ABG) and metabolic
parameters were unremarkable (Table 1). Due to the known
muscle dystrophy a total intravenous anaesthesia (TIVA)
supplemented with nondepolarising muscle relaxants was
carried out. Following 5min of preoxygenation anaesthesia
was induced with 1 µg/kg sufentanil, 2mg/kg propofol
and maintained with continuous propofol (5mg/kg/h) and
sufentanil (1 µg/kg/h) infusion. Rocuronium (0,6mg/kg)
was given to facilitate oral airway intubation and ventilation
was adjusted to ABG using low tidal volumes (4–6mL/kg).
Anticoagulation with heparin (500UI/kg) was monitored by
activated clotting time (ACT) in 20min intervals to maintain
ACT > 500 seconds. Tranexamic acid was administered
as loading dose of 15mg/kg within 15min followed by
continuous infusion of 2mg/kg for 6 hours. During induc-
tion of anaesthesia vital signs remained stable. After aortic
and bicaval cannulation, cardiopulmonary bypass (CPB)
was initiated and cardiac transplantation was performed
as described by Shumway and colleagues [6]. Reperfusion
phase was prolonged due to reduced donor organ function
with an estimated ejection fraction of 30%. Hence, an
intra-aortic balloon pump counterpulsation was inserted via
the left femoral artery. Afterwards, the patient was weaned
from CPB on epinephrine (0.07 µg/kg/min), norepinephrine
(0.25 µg/kg/min), enoximone (0.17mg/kg/h), and inhaled
nitric oxide (25 ppm). At this time, a lactic acidosis was
noticed, most likely caused by a prolonged episode of low
cardiac output (Table 1). Towards sternal closure hemody-
namic instability with sudden rise of pulmonal arterial pres-
sure to 60/24mmHg occurred. The sternum was reopened
and inhaled nitric oxide concentration was increased to
34 ppm. Subsequently the patient could be transferred to the
ICU in stable condition with an open chest. On the first
postoperative day the patient went to the operating room
for definite sternal closure and was extubated on the third
day after cardiac transplantation. Neurological status after
extubation was unaltered to initial findings and the patient
was discharged from hospital 30 days after transplantation.
2.1. In Vitro Contracture Test and Histological Findings. With
prior informed consent of the patient, two bundles of the
pectoralis major muscle were excised during the operative
procedure. According to the guidelines of the European
Malignant Hyperthermia Group an in vitro contracture test
was carried out and the muscle bundles were incubated with
increasing concentrations of caffeine (0.5; 1; 1.5; 2; 3; 4;
32mM), respectively, halothane (0.11; 0.22; 0.44; 0.66mM)
[7]. Neither caffeine nor halothane induced significant
muscular contractures at the threshold concentrations. There
was no evidence of pathologic sarcoplasmic calcium release
in response to malignant hyperthermia triggering agents in
this patient. Histology of pectoralis major muscle showed
mild myopathic changes with slightly increased variation in
fiber size, some atrophic fibers, internal nuclei and slight
increase of intramuscular fibrous tissue (Figure 1(a)). In the
ventricular myocardium many atrophic cardiomyocytes and
an increase of connective tissue were detected (Figure 1(b)).
3. Discussion
Due to lack of evidence in the current literature, the
choice of the best anaesthetic management for patients
with muscular dystrophies remains controversial. Several
case reports documented the safe application of inhalational
agents in patients with Duchenne and Becker type mus-
cular dystrophy [8]. On the other hand, rhabdomyolysis,
hyperkalemia and intraoperative or postoperative cardiac
arrest occurred in affected patients independently of the use
or absence of volatile anesthetics and/or the depolarising
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Figure 1: Histology (hematoxylin-eosin staining) of pectoralis major muscle (a) and heart muscle (b). In the pectorals major, mild
myopathic changes with hypotrophic fibers (asterisk), some internal nuclei (small arrow), and an increase of fibrous tissue (large arrow)
are seen. In the myocardium, there are some atrophic cardiomyocytes (small arrows) and a mild increase in connective tissue.
muscle relaxant succinylcholine [9]. Explicit recommenda-
tions or even guidelines concerning the anaesthetic practice
for patients with EDMD are not available. While spinal or
epidural anaesthesia were applied without any difficulty for
orthopaedic surgery [10–12] and caesarean sections [13, 14],
only two cases of uneventful general anaesthesia in EDMD
patients using enflurane and succinylcholine [11], or TIVA
[15] were described. In contrast to Duchenne and Becker
muscular dystrophy, caused by a mutation of the muscle-
stabilizing protein dystrophin, EDMD is associated with an
aberration of the inner nuclear membrane proteins emerin
or lamin A/C. As emerin and lamin A/C are suspected being
responsible for the fixation and stabilization of themyonuclei
during muscular contraction, alterations of these nuclear
membrane proteins may cause defective cellular signalling
in response to mechanical stimulations [16]. However, the
impact on sarcoplasmic calcium release remains cloudy [17].
The missing muscular response to caffeine and halothane in
the performed in vitro contracture test may be a hint that
exposition to triggering agents does not lead to a dysfunction
of calcium homeostasis in the lamin A/C phenotype. How-
ever, we should be cautious transferring in vitro results to in
vivo conditions and drawing conclusions based on this single
investigation. For safety reasons and in absence of significant
publications on anaesthesia in patients with EDMD we
decided to use TIVA in our patient. During and after
anaesthesia no signs of hypermetabolism or rhabdomyolysis
were observed. The lactic acidosis during reperfusion and
after weaning from CPB was most likely a result of the
initially reduced cardiac output of the transplanted organ,
while the increase of serum creatine kinase and myo-
globin were comparable to other major surgical procedures
[18].
Interestingly, the extent of cardiac involvement does
not correlate with the degree of skeletal muscle symptoms.
Progressive cardiomyopathy without peripheral muscular
symptoms similar to our patient has been previously
reported for lamin A/C phenotypes [19]. In affected patients
ECG abnormalities, for example, low amplitude P waves,
prolonged PQ interval and atrial fibrillation or flutter may
occur. These changes may proceed to atrial and ventricular
conduction blocks, possibly resulting in complete heart block
and necessitating temporary or permanent cardiac pacing.
During the course of the disease cardiomyopathy leading to
congestive heart failure may develop [4]. In patients with
significant cardiomyopathy myocardial depressant agents
should be avoided and cardiac pacing must be readily
available at any time in the perioperative period.
Early appearance of skeletal muscle contractures before
onset of muscular weakness is unique to EDMD. Involve-
ment of posterior-cervical muscles may significantly reduce
possible neck flexion and complicate endotracheal intu-
bation, even with a normal Mallampati score [15]. If
in doubt awake fiberoptic intubation should be preferred
to secure the airway. Furthermore, lumbar paravertebral
muscle contractures may hamper the application of spinal or
epidural anaesthesia [13].
In summary, we reported an uneventful general anaes-
thesia using TIVA for cardiac transplantation in a 19-year-
old woman suffering from EDMD. The in vitro contracture
test results of the patient suggest that exposition to triggering
agents does not induce a pathological sarcoplasmic calcium
release in the lamin A/C phenotype. However, due to the lack
of evidence in the literature, the authors would recommend
TIVA for patients with EDMD if general anaesthesia is
required.
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